• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Antibody decreases Zika virus levels and fetal transmission [PreClinical]

byCorinne FoleyandJessica Lau
November 24, 2016
in Infectious Disease, Obstetrics, Pediatrics, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Antibodies were isolated from patients with prior Zika virus infection and one specific antibody, ZIKV-117, decreased fetal transmission of Zika virus as well as viral replication in mice.

2. ZIKV-117 was efficacious at neutralizing the Zika virus when administered prophylactically and after virus exposure.

Evidence Rating Level: 2 (Good)

Study Rundown: Zika virus is known to cause microcephaly in fetuses and newborns as well as induce Guillain-Barré Syndrome in adults. Despite the pathogenic effects of Zika virus, there is currently no treatment or vaccine for this virus. Because of this, researchers in this study used serum from patients who had been infected with Zika virus and studied the potential use of their antibodies on eradicating the virus. The most inhibitory antibody, ZIKV-117, was tested in mice to determine its effects on viral eradication and fetal transmission of the virus.

First, mice were inoculated with the virus and then given a single dose of ZIKV-117. One dose of the antibody was able to significantly increase the survival of the mice. Next, knockout mouse models of placental transfer of Zika virus (Ifnar1-/- mice) were treated with ZIKV-117 and then infected with Zika virus. Reduced viral levels were noted in the maternal brain and serum. The pups also demonstrated a significant increase in survival compared to those that did not receive antibody. Similar results were seen in wildtype (WT) mice given anti-Ifnar monoclonal antibody (mAb) to mimic the human response to Zika virus. There was a lack of viral RNA in the placenta of the mice given ZIKV-117, and this antibody was able to reduce the placental transfer of Zika virus.

Although the ability of these results to be directly translated to humans is currently unclear, these results provide strong evidence for an antibody-based approach to the development of an efficacious treatment for Zika virus disease. Further, this approach could be efficacious as a prophylactic and post-exposure treatment for pregnant mothers.

Click to read the study in Nature

RELATED REPORTS

2 Minute Medicine Rewind January 28, 2019

A Zika vaccine could virtually eliminate prenatal infections

Zika virus exposure detected in patients presenting with new neuroinflammatory conditions

Relevant Reading: Zika Virus: Medical Countermeasure Development Challenges

In-Depth [animal study]: WT male mice were administered anti-Ifnar1 mAb and then given a mouse-adapted viral strain of ZIKV-Dakar. These mice were then treated with either 100 µg ZIKV-117 one day after infection or 250 µg five days after infection, with hCHK-152 given as an isotype control. Both treatment groups showed a significant increase in survival compared to the control (p<0.05), with 100% survival seen in the mice treated after day one.

Ifnar-/- pregnant dams were then treated with either ZIKV-117 or the isotype control at embryo day (E) 5.5 and then inoculated with ZIKV-Brazil at E6.5. The pups born showed a significant increase in survival (p<0.0001), with almost a 100% survival rate. In addition, there was a significant decrease in viral load in the maternal brain and serum (p<0.05).

Finally, the effect of the administration of ZIKV-117 before exposure to the Zika virus was tested in pregnant dams given anti-Ifnar1 mAb. Hematoxylin and eosin staining of the placenta revealed decreased placental damage and less trophoblast cell death. Fetal size was also found to be increased, and in situ hybridization showed an absence of viral RNA in the placenta of the treated animals. Similar results were obtained when ZIKV-117 was administered as a treatment after Zika virus exposure.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Zika
Previous Post

An analysis of emergency department visits for outpatient adverse drug events

Next Post

Lower threshold for abdominal aortic aneurysm repair linked to reduced mortality

RelatedReports

2 Minute Medicine Rewind January 28, 2019
Weekly Rewinds

2 Minute Medicine Rewind January 28, 2019

February 1, 2019
Stochastic resonance stimulation may decrease apnea of prematurity
Chronic Disease

A Zika vaccine could virtually eliminate prenatal infections

April 11, 2018
Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]
Chronic Disease

Zika virus exposure detected in patients presenting with new neuroinflammatory conditions

August 19, 2017
Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]
Infectious Disease

Adverse neurologic outcomes associated with maternal Zika virus infection

December 15, 2016
Next Post
Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

Lower threshold for abdominal aortic aneurysm repair linked to reduced mortality

Increased risk of stillbirth recurrence after a previous stillbirth

Palliative care likely to improve patient quality of life and reduce symptom burden

Ovarian cytology a poor screening test for malignancy in children

Molecular markers associated with bone marrow clearance in AML and MDS

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Evaluation of medical school parental leave policies in the United States
  • Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
  • Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options